Appendix 4D & Half-Year Report
Released
Released
Announcement PDF
Appendix 4D
Half-Year Report for the period ended 31 December 2023
Company Details
Name of entity:
ABN:
Reporting period:
Previous period:
PharmAust Limited
35 094 006 023
For the half-year ended 31 December 2023
For the half-year ended 31 December 2022
Results for announcement to the Market
Financial Performance
(AUD 000’)
Revenue
PharmAust Limited – Consolidated
Half-year ended Half-year ended
31 Dec 2023
31 Dec 2022
$000
$000
861
966
(Loss) before tax attributable to
members
(Loss) after tax attributable to members
(389)
(389)
(21)
(21)
Movement %
-11%
-1752%
-1752%
Review of Operations
Refer to Directors’ Report included in the attached half-year financial report.
Dividends
No Dividends were paid or declared for payment during the half-year period.
Net Tangible Asset Backing
Net tangible asset backing
Half-year ended 31 Dec 2023
1.16 cents
Loss of control over entities
Name of entities (or group of entities)
Epichem Pty Ltd
Date control loss
31/07/2023
Half-year ended 31 Dec 2022
0.25 cents
Auditor’s Review
The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.
The Interim Report of PharmAust Limited for the half year ended 31 December 2023 is attached.
Signed in accordance with a resolution of Directors.
On behalf of the Directors
Sam Wright
Director
Signed at Perth this 29th day of February 2024
1
PHARMAUST LIMITED
ABN 35 094 006 023
AND ITS CONTROLLED ENTITIES
Interim Financial Report
for the half-year ended 31 December 2023
C O N T E N T S
Directors' Report
3
Statement of Profit or Loss and Other Comprehensive Income
9
Statement of Financial Position
10
Statement of Changes in Equity
11
Statement of Cash Flows
12
Notes to the Financial Statements
13
Directors' Declaration
20
Independent Auditor’s Review Report
21
Auditor’s Independence Declaration
23
2
PHARMAUST LIMITED
DIRECTORS’ REPORT
The directors of PharmAust Limited submit the financial report of the consolidated entity for the half-year ended 31 December
2023.
DIRECTORS
The names of the directors who held office during or since the end of the half-year are:
Dr Roger Aston
Mr Neville Bassett AM
Mr Robert Bishop
Mr Sam Wright
Dr Thomas Duthy (appointed on 5 February 2024)
RESULTS
The operating loss for the consolidated entity for the half-year ended 31 December 2023 was $389,244 (2022: loss of $21,184).
PRINCIPAL ACTIVITIES
The principal continuing activities constituted by PharmAust Limited and the entities it controlled during the year were to develop
its own drug discovery intellectual property for the treatment of different types of cancers and neurological diseases.
REVIEW OF OPERATIONS
Research and Development
MOTOR NEURONE DISEASE PROGRAM
On 1 December 2023, PharmAust announced the successful completion of its Phase 1 MEND Study of monepantel (MPL) for
treating motor neurone disease (MND/ALS). This milestone was marked by all patients completing the study, with the release
of top-line results anticipated in Q1 CY24.
Importantly, all patients could swallow and breathe unassisted and expressed interest in participating in a 12-month Open-Label
Extension (OLE) Study. The Phase 1 MEND Study involved 12 patients with MND/ALS and aimed to determine the
recommended Phase 2 dose of MPL based on safety and preliminary efficacy.
A Safety Monitoring Committee oversaw the new dose levels during the progression of the study. There were no deaths or
treatment-related serious adverse events reported.
PharmAust also applied for Orphan Drug Designation (ODD) with the United States (US) Food and Drug Administration,
aligning with its plan to commence an adaptive Phase 2/3 study in H1 CY24. This designation could offer significant incentives,
including tax credits and 7-year market exclusivity post-approval.
In December, the Company announced that FightMND, Australia's leading not-for-profit foundation for Motor Neurone Disease
(MND) research, had invited the company to submit a complete grant application to support the Phase 2/3 clinical study. This is
a multicentre, randomised, placebo-controlled, adaptive Phase 2/3 clinical study aimed at evaluating the safety and efficacy of
MPL in patients with MND/ALS over 48 weeks.
The Company also announced that all 12 patients involved in the Phase 1 MEND Study were pleased and available to continue
treatment with MPL under a compassionate-use program administered by their treating physician, either Associate Professor
Susan Mathers or Professor Dominic Rowe, to be eligible for the OLE study that is due to commence early in 2024.
3
PHARMAUST LIMITED
DIRECTORS’ REPORT (continued)
VETERINARY ONCOLOGY STUDY
During October, the Company announced positive top-line data from its Phase 2 veterinary clinical study of MPL for treating
Canine B-Cell Lymphoma. The study, designed as a Phase 2 open-label, single-arm dose-finding study, involved various MPL
dosing regimens to determine the most effective and safe treatment option.
The study yielded encouraging results, showing that MPL treatment was safe, well-tolerated, and resulted in no treatment-related
deaths or severe adverse reactions. The Overall Clinical Benefit was 35% (14 out of 40 dogs), with a median Time to Progression
(TTP) of 28 days, favourably compared to the most recent FDA-approved product for B-cell and T-cell lymphoma,
LAVERDIATM. MPL also demonstrated a significant competitive advantage over LAVERDIATM in terms of Quality of Life
(QoL) and Level of Function (LoF) as assessed by dog owners.
B-Cell Lymphoma is an aggressive form of cancer – without treatment it is often fatal within weeks of diagnosis. PharmAust’s
studies have shown MPL extends survival three-fold to a median of 150 days while maintaining excellent quality of life.
Significantly, MPL is a cost-effective way for owners to safely manage their pet’s cancer at home, an important factor in the
viability of a commercial companion animal drug.
Given these positive outcomes, PharmAust plans to use this data to open an Investigational New Animal Drug (INAD)
application with the United States Food and Drug Administration’s Center for Veterinary Medicine (CVM) and proceed with
pivotal studies in 2024 to support product registration.
Earlier in the reporting period PharmAust announced an additional milestone in the Phase 2 veterinary study, with a patient in
the canine trial surpassing 365 days with stable disease and continued excellent quality of life.
EPICHEM LIQUIDATION
PharmAust announced the voluntary liquidation of its wholly owned subsidiary Epichem. The decision was largely due to the
loss of the longstanding DNDi research contract that funded Epichem to research new treatments for neglected diseases. Epichem
then operated at a loss that was funded by PharmAust.
Epichem, as a CRO, heavily relied on the pharmaceutical sector which has been significantly impacted by COVID-19 and other
movements in the industry.
CORPORATE
Key Management Hires
In August, PharmAust appointed Dr Michael Thurn as Chief Executive Officer (CEO). Dr Thurn has substantial experience in
drug discovery, development, regulation and commercialisation through leadership roles ranging from research organisations to
publicly listed biotechnology companies.
His previous responsibilities have included leading a variety of US Food and Drug Administration (FDA) Investigational New
Drug (IND) applications across a range of therapeutic areas and the evaluation of drugs and vaccines for registration in Australia
as a part of the Drug Safety Evaluation Branch (DSEB) of the Therapeutics Goods Administration (TGA).
Michael has also been responsible for the execution of Phase 1 and 2 clinical trials and business development activities across
animal and human health products. He possesses strong entrepreneurial, leadership and management skills that have seen him
achieve outstanding results over a 25-year career in the biotechnology industry, including co-founding MARP Therapeutics and
roles with Botanix Pharmaceuticals (ASX:BOT), Mimetica, Spinifex Pharmaceuticals, Cytopia, Xenome and Novogen. During
this time, Michael has gained Australian and US capital markets exposure and has successfully accessed funding through private
and public channels, partnerships and non-dilutive means.
4
PHARMAUST LIMITED
DIRECTORS’ REPORT (continued)
Dr Roger Aston remains Chairman of the Board and has transitioned into a non-executive role. He continues to advise PharmAust
with his 40 years’ experience in the pharmaceutical and healthcare industry.
Dr Carol Worth joined the Company as the Chemistry, Manufacturing and Controls (CMC) Operations Manager, bringing over
30 years of experience in the pharmaceutical industry. Her expertise is expected to significantly contribute to the GMP
manufacture of MPL and provide clinical supplies for upcoming studies.
John Clark was appointed to the role of Clinical Operations Manager during the period. He has over 20 years of experience
managing global phase I – IV clinical trials and his role will focus on leading global clinical operations as PharmAust positions
itself as a leading developer in neurodegenerative medicines.
Subsequent to balance date, in February highly regarded biotechnology executive and advisor Dr Thomas Duthy was appointed
as a Non-Executive Director of PharmAust. Dr Duthy has over 19 years of direct financial market and executive level/Board
experience with ASX-listed companies. He is a Director and Founder of Nemean Group, which provides corporate advisory and
investor relations (IR) services in the Life Sciences and Technology sectors.
Funding Activities
PharmAust raised approximately $3.46 million during December through an oversubscribed placement led by Blue Ocean
Equities at a 10.8% premium to the 30-day volume-weighted average price (VWAP), reflecting growing confidence from new
institutional shareholders in the Company's achievements and prospects.
Specialist institutional investor Merchant Biotech Fund and associated parties applied for $2.1m, while the remaining $1.4
million was placed with other institutional and sophisticated investors, including PharmAust’s Finance Director and Company
Secretary, Sam Wright.
In November 2023, PharmAust initiated an Options Offer to holders of lapsed PAAO Listed Options, aiming to raise to
$396,124.56 by offering new options at 0.5 cents each. This strategic financial move was designed to bolster the Company’s
funding for its ongoing and future projects. The Offer concluded with an impressive 93% uptake, resulting in a total subscription
of $367,747.68.
PharmAust also announced the receipt of a refund from the Australian Taxation Office (ATO) under the Research and
Development Tax Incentive (RDTI) scheme. The company received a sum of $553,435.28 as a refundable amount on its 2023
Tax Return. The RDTI scheme, jointly administered by the ATO and AusIndustry, provides up to a 43.5% refundable tax offset
on eligible expenses for research and development activities.
ANNUAL GENERAL MEETING
On 20 November 2023, PharmAust held its Annual General Meeting of Shareholders at the offices of RSM Australia, Level 21,
55 Collins St, Melbourne VIC 3000.
All resolutions that were put were passed by a poll.
SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS
On 31 July 2023, the consolidated entity put Epichem Pty Limited (EPC) into voluntary liquidation, as a result, the group loss
control of EPC.
Other than the above, there were no significant changes in the state of affairs of the consolidated entity during the financial halfyear.
5
PHARMAUST LIMITED
DIRECTORS’ REPORT (continued)
SUBSEQUENT EVENTS
On 27 February, the Company announced that it has met its primary safety and tolerability endpoints with monepantel (MPL)
and, importantly, demonstrated a positive signal of potential efficacy. Rates of disease progression in patients with Motor
Neurone Disease (MND) / Amyotrophic Lateral Sclerosis (ALS) measured by changes in ALSFRS-R may be slowed by 58%
for Cohort 2, when compared to an external control cohort (PRO-ACT database).
On 16 February 2024, the Company announced it had successfully completed a pre-IND meeting with the FDA, who provided
positive feedback and outlined the path required to potentially receive accelerated and full approval of monepantel for the
treatment of MND/ALS. PharmAust will initiate requirements requested by the FDA in the preparation to open an IND
application for the adaptive Phase 2/3 clinical study.
Earlier in February PharmAust announced the commencement of its 12-month Open-Label Extension study in MND/ALS
patients, after all 12 patients from the Phase 1 MEND Study requested to be enrolled, meeting the minimum requirement of
being able to swallow. This followed the earlier announcement of Ethics Committee Approval of the extension study.
This announcement also outlined that statistical survival estimations based on comparisons to the PRO-ACT historical
MND/ALS database, points to the probability that all 12 patients treated with monepantel being alive today being less than 1 in
1,000.
In January the Company received feedback from the FDA with regards to the Orphan Drug Designation (ODD) application for
MPL. The FDA requested clinical trial data to support the granting of ODD for the treatment of MND/ALS, with data from the
Phase 1 MEND Study due for released in Q1 CY24. The FDA will allow PharmAust to submit an amendment to its ODD
application rather than reapplying with an entirely new application.
On 16 January 2024 PharmAust announced it has partnered with leading MND/ALS clinical study design and statistical analysis
specialists Berry Consultants. US-based Berry Consultants has a strong track-record of innovative clinical trial design and
experience with the FDA, as well as being part of the advisory committee meeting for the recent FDA accelerated approval of
Amylyx Pharmaceutical’s Relyvrio® for MND/ALS. Berry has also been integral to the Healey ALS Platform Trial. Berry will
oversee the design of PharmAust’s adaptive Phase 2/3 study to best position monepantel for FDA approval for the treatment of
MND/ALS.
On 19 January 2024, the Company issued 1,125,000 Performance Rights to John Clark under the Employee Incentive Plan.
On 19 January 2024, the Company issued 1,000,000 options to Dr Michael Thurn and 250,000 options to John Clark (Exercise
Price of 17.5 cents and expiry date 19/01/2026)
On 6 February 2024, the Company issued 1,020,948 shares from the exercise of PAAOA options.
On 13 February 2024, the Company issued 500,000 shares to Dr Michael Thurn from the achievement of milestone 1 of his
Performance Rights being, prior to 31/8/25, the Company achieves a market capitalisation of at least $50,000,000 for a
continuous period of 20 Trading Days on which Shares have actually traded.
On 23 February 2024, the company issued 450,000 shares and 300,000 PAAOA options to Sam Wright for the third tranche of
the Placement as per Appendix 3B dated 18 December 2023 and approved by shareholders on Wednesday 21 February 2024.
On 23 February 2024, the Company issued 280,000 shares to NWR Communications Pty Ltd as consideration for 6 months
investor and media relations.
On 23 February 2024, the Company issued 1,500,000 advisor options (Exercise Price of 17.5 cents and expiry date 19/01/2026)
as per the terms of a mandate agreement dated 15 January 2024. The options were issued as consideration for 12 months corporate
advisory focused on introductions to high quality institutional and sophisticated investors, which are likely to strengthen the
company’s share register and be supportive of PAA’s long-term strategic objectives.
On 28 February 2024, the Company issued 1,185,220 shares from the exercise of options.
Apart from the above, no other matter or circumstance has arisen since 31 December 2023 that has significantly affected, or may
significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs
in future financial years.
6
PHARMAUST LIMITED
DIRECTORS’ REPORT (continued)
AUDITOR’S INDEPENDENCE DECLARATION
A copy of the auditor’s independence declaration as required under section 307C of the Corporations Act 2001 is included within
this financial report.
This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.
On behalf of the directors
Sam Wright
Director
Signed at Perth this 29th day of February 2024
7
General information
The financial statements cover PharmAust Limited as a consolidated entity consisting of PharmAust Limited and the entities it
controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is PharmAust
Limited's functional and presentation currency.
PharmAust Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and
principal place of business are:
Registered office
Principal place of business
Suite 116/1 Kyle Way
Claremont WA 6010
Suite 116/1 Kyle Way
Claremont WA 6010
A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report,
which is not part of the financial statements.
The financial statements were authorised for issue, in accordance with a resolution of directors, on 29th February 2024.
8
PHARMAUST LIMITED
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
For the half-year ended 31 December 2023
Note
Revenue
Other income
Total revenue
3
3
Research and development expenses
Share-based payment (expense)/reversal
Administration expenses
Employee benefits expense
Total expenses
Income tax expense
(Loss) after income tax expense from continuing
operations
Profit after income tax expense from discontinued
operations
6
Other comprehensive income
Total comprehensive loss for the half-year
Basic and diluted (loss) per share from continuing
operations attributable to the owners of PharmAust
Limited (cents per share)
Basic and diluted earnings per share for profit from
discontinued operations attributable to the owners
of PharmAust Limited (cents per share)
Consolidated
31 December
31 December
2023
2022
$
$
861,302
861,302
967,199
967,199
(1,324,355)
(76,616)
(740,644)
(323,002)
(2,464,617)
(429,581)
92,506
(495,895)
(202,144)
(1,035,114)
-
-
(1,603,315)
(67,915)
1,214,071
46,731
(389,244)
(21,184)
Cents
Cents
(0.46)
(0.02)
0.35
0.01
The above statement of profit and loss and other comprehensive income should be read in conjunction with the accompanying
notes.
9
PHARMAUST LIMITED
STATEMENT OF FINANCIAL POSITION
As at 31 December 2023
Note
Consolidated
31 December
30 June
2023
2023
$
$
CURRENT ASSETS
Cash and cash equivalents
Trade and other receivables
Other current assets
TOTAL CURRENT ASSETS
5,451,622
128,418
5,580,040
2,705,941
148,233
167,054
3,021,228
NON-CURRENT ASSETS
Intangible assets
Property, plant and equipment
TOTAL NON-CURRENT ASSETS
3,107,477
1,641
3,109,118
3,107,476
1,641
3,109,117
TOTAL ASSETS
8,689,158
6,130,345
CURRENT LIABILITIES
Trade and other payables
Provisions
Lease liabilities
Accrued Expenses
1,096,835
75,232
54,450
873,485
262,786
158,454
52,641
TOTAL CURRENT LIABILITIES
1,226,517
1,347,366
-
3,341
890,503
893,844
TOTAL LIABILITIES
1,226,517
2,241,210
NET ASSETS
7,462,641
3,889,135
61,170,220
3,140,552
(56,848,131)
57,632,711
2,715,313
(56,458,889)
7,462,641
3,889,135
NON-CURRENT LIABILITIES
Provisions
Lease liabilities
TOTAL NON-CURRENT LIABILITIES
EQUITY
Issued capital
Options and performance rights reserve
Accumulated losses
5
4
TOTAL EQUITY
The above statement of financial position should be read in conjunction with the accompanying notes.
10
PHARMAUST LIMITED
STATEMENT OF CHANGES IN EQUITY
For the half-year ended 31 December 2023
Note
As at 1 July 2022
Issued Capital
Accumulated
Losses
$
$
Note
As at 1 July 2023
Loss for the period
Total comprehensive loss for
the period
Transactions with owners in
their capacity as owners:
Shares issued (net of costs)
Issue of options (net of costs)
Share-based payments
As at 31 December 2023
4
Total
$
55,343,941
(50,247,327)
2,747,820
7,844,434
-
(21,184)
-
(21,184)
-
(21,184)
-
(21,184)
-
-
(92,506)
(92,506)
55,343,941
(50,268,511)
2,655,314
7,730,744
Issued Capital
Accumulated
Losses
$
$
Options and
Performance
rights reserve
$
Loss for the period
Total comprehensive loss for
the period
Transactions with owners in
their capacity as owners:
Share-based payments
As at 31 December 2022
Options and
Performance
rights reserve
$
Total
$
57,632,710
(56,458,887)
2,715,312
3,889,135
-
(389,244)
-
(389,244)
-
(389,244)
-
(389,244)
3,487,510
50,000
-
409,850
15,390
3,487,510
409,850
65,390
61,170,220
(56,848,131)
3,140,552
7,462,641
The above statement of changes in equity should be read in conjunction with the accompanying notes.
11
PHARMAUST LIMITED
STATEMENT OF CASH FLOWS
For the half-year ended 31 December 2023
Consolidated
31 December
31 December
2023
2022
$
$
CASH FLOWS FROM OPERATING ACTIVITIES
Receipts from customers
Payments to suppliers and employees
Interest received
Other income
Interest paid
Net cash (used in) operating activities
146,823
(1,055,765)
4,110
857,560
(47,272)
1,548,951
(2,578,744)
2,240
993,185
(42,014)
(76,382)
CASH FLOWS FROM INVESTING ACTIVITIES
Payments for plant and equipment
Payments for intangible assets
Cash outflow on disposal of subsidiary
Net cash (used in) investing activities
(165,227)
(165,227)
(260)
(168)
(428)
CASH FLOWS FROM FINANCING ACTIVITIES
Net repayment of borrowings
Repayment of lease liabilities
Proceeds from issue of shares
Payments of share issue costs
Proceeds from issue of options
Net cash from/(used in) financing activities
2,575,869
(13,814)
396,125
2,958,180
(210,116)
(67,101)
(277,217)
Net movement in cash and cash equivalents
2,745,681
(354,027)
Cash and cash equivalents at the beginning of the
financial period
Cash and cash equivalents at the end of the financial
period
2,705,941
2,415,616
5,451,622
2,061,589
6
The above statement of cash flows should be read in conjunction with the accompanying notes.
12
PHARMAUST LIMITED
NOTES TO THE FINANCIAL STATEMENTS
For the half-year ended 31 December 2023
1.
MATERIAL ACCOUNTING POLICY INFORMATION
These general purpose financial statements for the interim half-year reporting period ended 31 December 2023
have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial
Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with
AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial
Reporting'.
These general purpose financial statements do not include all the notes of the type normally included in annual
financial statements. Accordingly, these financial statements are to be read in conjunction with the annual
report for the year ended 30 June 2023 and any public announcements made by the company during the interim
reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.
The principal accounting policies adopted are consistent with those of the previous financial year and
corresponding interim reporting period, unless otherwise stated.
Discontinued operations
A discontinued operation is a component of the consolidated entity that has been disposed of or is classified
as held for sale and that represents a separate major line of business or geographical area of operations, is part
of a single co-ordinated plan to dispose of such a line of business or area of operations, or is a subsidiary
acquired exclusively with a view to resale. The results of discontinued operations are presented separately on
the face of the statement of profit or loss and other comprehensive income.
NEW OR AMENDED ACCOUNTING STANDARDS AND INTERPRETATIONS ADOPTED
The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations
issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting
period.
Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early
adopted.
2.
SEGMENT INFORMATION
The consolidated entity has determined the operating segments based on the reports reviewed by the Board of
Directors that are used to make strategic decisions. The Board of Directors has considered the business from
both a geographic and business segment perspective and the following are the reportable segments under
AASB 8.
Corporate
Research
Pharmaceutical
Total
(Continuing)
(Discontinued)
$
$
$
$
31 December 2023
Revenue
External sales
82,684
82,684
Other external revenue
860,706
596
369
861,671
Total revenue
860,706
596
83,053
944,355
13
PHARMAUST LIMITED
NOTES TO THE FINANCIAL STATEMENTS
For the half-year ended 31 December 2023
2.
SEGMENT INFORMATION (CONTINUED)
Corporate
$
Pharmaceutical
(Discontinued)
$
Total
$
31 December 2023
Results
Segment net (loss) before tax
Interest income
(1,603,842)
3,359
527
596
1,214,071
-
(389,244)
3,955
Segment assets
Segment operating assets
5,514,859
3,174,299
-
8,689,158
Segment liabilities
Segment operating liabilities
(1,226,517)
-
-
(1,226,517)
Corporate
Research
(Continuing)
$
Pharmaceutical
(Discontinued)
$
31 December 2022
Revenue
External sales
Other external revenue
Total revenue
Results
Segment net profit (loss) before
tax
Interest income
3.
Research
(Continuing)
$
$
Total
$
966,620
966,620
579
579
-
967,199
967,199
(68,494)
579
46,731
(21,184)
1,342
579
-
1,921
CONSOLIDATED
31 DECEMBER 31 DECEMBER
2023
2022
$
$
REVENUES
Revenue from contracts with customers
Sale of goods
Rendering of services
Other revenue
Interest income
R&D tax incentive
Grant income received
Other revenue
Timing of revenue recognition
Goods delivered at a point in time
Services delivered over time
14
-
-
3,955
553,435
288,277
15,635
861,302
1,920
654,109
311,170
967,199
861,302
861,302
967,199
967,199
PHARMAUST LIMITED
NOTES TO THE FINANCIAL STATEMENTS
For the half-year ended 31 December 2023
4.
CONSOLIDATED
31 DECEMBER
30 JUNE
2023
2023
$
$
OPTIONS AND PERFORMANCE RIGHTS RESERVE
Options reserve
Performance rights reserve
Options
Balance at
1 July 2023
No.
97,608,642
3,125,162
15,390
3,140,552
Granted
Exercised
Expired/ Other
No.
99,132,421
No.
(3,724)
No.
(79,224,912)
2,715,313
2,715,313
Balance at 31
December 2023
No.
117,512,427
The weighted average remaining contractual life of options outstanding at period-end was 2.33 years (30 June 2023:
0.79 years).
Granted
Exercised
Lapsed/ Other
Performance rights
Balance at
1 July 2023
No.
-
No.
2,400,000
No.
-
No.
-
No of rights issued
150,000
Grant date
1 September 2023
Fair value
$0.075
Milestone
The executive is engaged as an employee for a
continuous period of 3 months from the
commencement date.
500,000
1 September 2023
$0.030
Prior to 31 August 2025, the Company achieves a
market capitalization of at lease $50 million for a
continuous period of 20 trading days on which
shares have traded.
750,000
1 September 2023
$0.014
Prior to 31 August 2025, the Company achieves a
market capitalization of at least $75 million for a
continuous period of 20 trading days on which
shares have traded.
1,000,000
1 September 2023
$0.0079
Prior to 31 August 2025, the Company achieves a
market capitalization of at least $100 million for a
continuous period of 20 trading days on which
shares have traded.
15
Balance at 31
December 2023
No.
2,400,000
PHARMAUST LIMITED
NOTES TO THE FINANCIAL STATEMENTS
For the half-year ended 31 December 2023
5.
ISSUED CAPITAL
CONSOLIDATED
31 DECEMBER
31 DECEMBER
2023
SHARES
30 JUNE
2023
SHARES
2023
$
30 JUNE
2023
$
374,065,597
347,474,940
61,170,220
57,632,711
ISSUE PRICE
$
NO OF SHARES
Ordinary shares – fully paid
Movement in fully paid ordinary shares;
1 July
Issuance of shares
Conversion of options
Issuance to advisor
Issuance of shares
Cash received in advance pending allotment of shares*
Share issue costs
0.08
0.20
0.07
0.10
347,474,940
1,300,000
3,724
675,676
24,611,257
374,065,597
*10,750,000 shares were issued at $0.10 per share on 2 January 2024 with respect to capital raising.
6.
$
57,632,711
104,000
744
50,000
2,499,503
1,075,000
(191,738)
61,170,220
DISCONTINUED OPERATIONS
On 31 July 2023, the consolidated entity put Epichem Pty Limited (EPC) into voluntary liquidation, as a result, the
group loss control of EPC and EPC was classified as a discontinued operations for the half year ended 31 December
2023.
Financial performance information
CONSOLIDATED
31 DECEMBER 31 DECEMBER
2023
2022
$
$
82,684
1,915,093
369
29,247
83,053
1,944,340
Sales of good
Interest
Total revenue
Raw materials and consumables used
Administration expenses
Employees benefits expenses
Depreciation and amortisation expenses
Interest expenses
Total expenses
(7,029)
(61,964)
(146,491)
(215,484)
(169,071)
(443,339)
(1,079,693)
(163,492)
(42,014)
(1,897,609)
(Loss)/Profit before income tax expenses
Income tax expense
(132,431)
-
46,731
-
(Loss)/Profit after income tax expense
(132,431)
46,731
Profit on disposal before income tax
Income tax expense
1,346,502
-
-
Profit on disposal after income tax expense
1,346,502
-
Profit after income tax expense from discontinued operations
1,214,071
46,731
16
PHARMAUST LIMITED
NOTES TO THE FINANCIAL STATEMENTS
For the half-year ended 31 December 2023
6.
DISCONTINUED OPERATION (CONTINUED)
Cash flow information
Net cash (used in)/from operating activities
Net cash used in investing activities
Net cash used in financing activities
Net (decrease)/increase in cash and cash equivalents from
discontinue
Share your feedback
Discover